Research programme: pure estrogen receptor antagonists - ProStrakan

Drug Profile

Research programme: pure estrogen receptor antagonists - ProStrakan

Alternative Names: PSK-3668

Latest Information Update: 19 Sep 2007

Price : $50

At a glance

  • Originator ProStrakan
  • Class Antineoplastics
  • Mechanism of Action Estrogen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 19 Sep 2007 Discontinued - Preclinical for Cancer in Europe (unspecified route)
  • 19 Apr 2006 This programme is still in active development
  • 22 Sep 2004 ProSkelia has merged with Strakan to form ProStrakan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top